Liquid Biopsy Results for 162 Metastatic Breast Cancer Patients

162 patients with HR-positive, HER2-negative metastatic breast cancer underwent liquid biopsy testing in routine clinical care. The data, published on figshare in 2026, includes mutation profiles for ESR1, PIK3CA, PTEN, and AKT genes. Results show ESR1 mutations were detected in 28.4% of patients and directly influenced treatment decisions.

Use Cases

• Analyzing the prevalence and therapeutic implications of ESR1 mutations based on the reported 28.4% detection rate.
• Studying the real-world feasibility and turnaround time (~8.7 days) of liquid biopsy implementation in clinical practice.
• Investigating co-occurrence patterns of mutations in genes like PIK3CA, PTEN, and AKT mentioned in the results.
• Modeling treatment decision pathways based on molecular findings, such as the use of elacestrant for 43.5% of patients with ESR1 mutations.

Strengths

• Data from 162 patients provides a substantive cohort for real-world analysis.
• High read depth (~5,000–7,000×) next-generation sequencing suggests detailed mutation profiling.
• Clear clinical outcome linkage: ESR1 detection led to targeted therapy (elacestrant) for 20 patients.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data may reflect temporal or clinical practice bias inherent to the single retrospective study.

Provenance

Source

figshare admin karger

Collection Method

Retrospective analysis of patients who underwent liquid biopsy testing in routine clinical care.

Freshness

Last updated 2026-05-22 11:55:20; freshness should be verified.